Nick Tate
Nick Tate Senior Editorial Manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.
Nick Tate is the senior editorial manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.
As a best-selling author, seasoned journalist and TV commentator specializing in health care, finance and biotech, Nick is all about big ideas and innovations — always keeping his followers informed on the next big thing.
His work has appeared in The Miami Herald, The Atlanta Journal-Constitution, South Florida Business Journal, Newsmax Magazine, South Florida Sun Sentinel, Boston Herald, and on Newsmax TV and the Al Jazeera network.
His top-selling book, the ObamaCare Survival Guide, was on the Publishers Weekly and The New York Times best-sellers lists for 22 weeks — reaching No. 1 on The Times list for paperback advice books.
Tate also co-authored DaVinci’s Baby Boomer Survival Guide: Live, Prosper, and Thrive in Your Retirement. And he published two other books — the Encyclopedia of Natural Healing and The Sick Building Syndrome — following a year-long journalism fellowship at the Harvard School of Public Health.
Tate’s three-decades-long commitment to keeping the public well-informed is why Banyan Hill Publishing recruited him in 2018 to join Paul Mampilly’s team. You can now read Nick’s weekly analysis in Bold Profits Daily as he guides over 130,000 readers on the best ways to grow their wealth.
Nick Tate's Articles
Meatless Burger IPO Nets Investor-Advocate 1,570% Gains May 17, 2019- Beyond Meat’s stock skyrocketed 163% when it went public earlier this month. It’s proof the global market for meatless foods is booming and that IPOs are a great way to invest in companies and causes you believe in — and pocket big profits at the same time.
$105 Million IPO Spotlights Organ Transplant Opportunity May 10, 2019- The global organ-transplantation market is projected to hit $51 billion in just six years. Here’s how to double your money and cash in with an ETF, and double your money in a year.
2 Picks for the DNA Test Boom May 2, 2019- The market for full-genome DNA testing will hit 60 million by 2021 with a new $100 test in the pipeline — a milestone likely to deliver huge gains to investors who get in on this mega medical trend now.
IPO Play for the Meatless Burger Boom April 26, 2019- Beyond Meat could be valued at $1.2 billion when it goes public. It’s proof the global market for meatless foods is booming. With 40 million Americans going vegan or vegetarian, now’s the time to buy into the mega meatless trend.
4,500% Biotech Opportunity: Needle-Free Diabetes Devices April 19, 2019- We are at the forefront of a massive biotech opportunity. Two big diabetes advances are going to make needles obsolete, and investors wealthy.
2 Picks to Capitalize on Telehealth Growth April 12, 2019- Telemedicine is reviving the idea of a house call, letting teledocs “meet” with patients via video. With telehealth set to become a $130 billion industry by 2025, now’s a great time to capitalize on the investment and health care opportunity it presents.
SoftBank Robotics is Changing the Face of Health Care April 5, 2019- Artificially intelligent robots and other “thinking” machines are entering the new high-tech health care workforce. They will not only help you be healthier, but investing in the new tech could make you wealthier as well. Here’s two ways to do it. 
Investing in Alzheimer’s Disease Treatment Stocks March 29, 2019- There hasn’t been a new Alzheimer’s treatment in 16 years, with Big Pharma logging hundreds of dismal drug failures. But a new way of treating Alzheimer’s disease is showing great promise, offering great opportunity for individuals at risk and biotech investors alike.
Tesla, Fintech, Smart Homes — Disruptors on Our Radar March 23, 2019- Invest in the new. It’s the chief mantra of our Bold Profits plays and recommendations — and a reason we’re beating the S&P 500 Index by a wide margin.
2 Ways to Invest in the Genetics Revolution March 22, 2019- Advances in gene therapy are the reason it’s shaping up to be the biggest year for biotech breakthroughs and investments. Here are two ways to invest.
